Related Experiment Video

Updated: Jul 19, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.3K

Implantable Devices in Genetic Heart Disease: Disease-Specific Device Selection and Programming

Simon Hansom1, Zachary Laksman2

  • 1Division of Cardiology, Arrhythmia Service, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.

Cardiac Electrophysiology Clinics
|August 9, 2023
PubMed

Insights

Diagnosing rare genetic heart diseases is difficult due to limited data. This research focuses on improving implantable cardioverter defibrillator (ICD) use for better patient protection and fewer complications.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Devices

Background:

  • Rare genetic heart diseases present diagnostic and risk stratification challenges.
  • Limited data hinder randomized controlled trials for these conditions.
  • Implantable cardioverter defibrillators (ICDs) are crucial for managing ventricular arrhythmias but carry risks.

Purpose of the Study:

  • To address the clinical challenges in diagnosing and stratifying risk for rare genetic heart diseases.
  • To optimize the use of ICDs for protecting high-risk patients while minimizing risks for low-risk individuals.
  • To ensure appropriate ICD programming for maximal patient benefit and safety.

Main Methods:

  • Review of existing clinical data and guidelines for rare genetic heart diseases.
  • Analysis of patient outcomes related to ICD implantation and programming.
  • Comparative assessment of risk stratification strategies.

Main Results:

  • Current diagnostic and risk stratification methods for rare genetic heart diseases are insufficient.
  • There is a need for improved strategies to identify patients who will benefit from ICDs.
  • Appropriate ICD programming is critical for balancing efficacy and safety.

Conclusions:

  • Enhanced diagnostic and risk stratification tools are needed for rare genetic heart diseases.
  • Optimized ICD implantation and programming protocols are essential for patient care.
  • Further research is required to refine management strategies for these complex conditions.

Keywords:
ArrhythmiaDefibrillatorGeneticInheritedProgramming

More Related Videos

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

11.2K
A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice06:42

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice

Published on: April 16, 2018

16.1K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11